FDA clears Evolva’s IND for EV-077 in influenza
Evolva Holding SA announced that the US Food and Drug Administration (FDA) has cleared Evolva’s request to test EV-077 in man, under an Investigational New Drug (IND) application for influenza.
Neil Goldsmith, CEO and Managing Director of Evolva commented: “This regulatory clearance by the FDA is an important milestone in the development of EV-077. In preclinical testing, EV-077 has shown potential as prophylaxis and treatment of various viral infections. We believe the compound could have significant potential against influenza and in bio-defence.”
Evolva has entered into discussions with potential partners regarding the further development and marketing of the compound. Evolva owns the rights to all intellectual property surrounding EV-077.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
The adult generations of today are less healthy than their counterparts of previous generations - Results from a large cohort study suggest that exposure to metabolic risks of cardiovascular disease is increasing
List_of_diseases_(I)
